SI-BONE, Inc. (SIBN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company raised its guidance midpoint due to strong Q3 performance and expects continued positive momentum in Q4. They achieved positive cash flow from operating activities and have a strong product pipeline with international growth prospects. Gross margins exceeded expectations, and they anticipate further improvement. Despite some vague responses, the overall sentiment from the Q&A is positive, with strong growth drivers and strategic initiatives in place.
Key Financial Performance
Worldwide Revenue $48.7 million in the third quarter, representing approximately 21% growth year-over-year. This growth was driven by healthy demand trends, disciplined execution, and the launch of iFuse-TORQ in Europe.
U.S. Revenue $46.4 million, representing 21.2% growth year-over-year. This was driven by growing adoption of solutions and procedure volume growth of over 22%.
International Revenue $2.3 million, representing 10.2% growth year-over-year. Growth was fueled by the launch of iFuse-TORQ and increasing adoption trends.
Gross Profit $38.8 million, an increase of $6.9 million or 21.8% year-over-year. Gross margin expanded by 75 basis points to 79.8%, driven by disciplined pricing strategy and supply chain optimization.
Operating Expenses $44.2 million, an increase of $4.7 million or 11.9% year-over-year. The increase reflects growth-related investments, higher commissions from increased revenue, and elevated G&A spending.
Net Loss $4.6 million, narrowed from $6.6 million year-over-year. This improvement reflects better operational efficiency and revenue growth.
Adjusted EBITDA $2.3 million, translating to an adjusted EBITDA margin of approximately 5%. This is a significant improvement from an adjusted EBITDA loss of $11.7 million in the prior year period.
Cash from Operating Activities $2.3 million, marking the first quarter of meaningful positive cash flow from operating activities. This milestone reflects increasing scale and an asset-light business model.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
iFuse-TORQ commercialization in Europe: Successfully launched iFuse-TORQ in Europe, contributing to international revenue growth.
New products for 2026: Significant progress on two new products expected to launch in 2026.
Granite 9.5: Expanding into the degenerative spine procedure market with Granite 9.5, targeting nearly 100,000 annual procedures.
iFuse-TORQ TNT: Breakthrough technology for sacral insufficiency fractures, a $300 million market opportunity, with strong clinical reception and distributor interest.
Third breakthrough device: Incorporates engineering and biomechanical learnings, expected to commercialize by late 2026.
U.S. revenue growth: Revenue grew over 21% to $46.4 million, driven by growing adoption of solutions.
International revenue growth: International revenue grew by 10.2%, with expectations for acceleration in 2026 due to iFuse-TORQ.
Physician engagement: Added 330 physicians in Q3 2025, marking the largest quarterly increase in company history.
Revenue growth: Worldwide revenue reached $48.7 million, a 20.6% increase.
Profitability: Achieved positive adjusted EBITDA of $2.3 million, with a margin of approximately 5%.
Cash flow: Generated $2.3 million in cash from operating activities, achieving positive operating cash flow for the first time.
Innovation focus: Focused on improving surgical outcomes for patients with compromised bone and expanding the application of existing technologies.
Reimbursement improvements: CMS finalized a 17% increase in reimbursement for office-based SI joint procedures, benefiting interventional business.
Territory expansion: Plan to increase the number of territories to capitalize on market opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is actively pursuing regulatory clearance to commercialize additional products across several international markets, which could delay international growth if not achieved as planned.
Reimbursement Changes: Proposed reimbursement changes, such as the transitional pass-through payment for Granite and the NTAP for TNT, are critical for the company's financial performance. Any unfavorable changes could negatively impact revenue.
Supply Chain Costs: Higher instrument depreciation and freight costs were noted, which could pressure gross margins if not managed effectively.
Market Penetration: The company is expanding into underpenetrated markets, but success depends on physician adoption and market acceptance of new products.
Product Launch Timelines: Delays in FDA approvals or product launches, such as the next-generation technology expected in 2026, could impact revenue growth and market positioning.
Economic Conditions: Broader economic uncertainties could affect hospital budgets and physician adoption rates, impacting the company's revenue.
Operational Expenses: Increased operating expenses, including growth-related investments and higher commissions, could strain profitability if revenue growth slows.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Updated full-year revenue guidance to range between $198 million to $200 million, implying year-over-year growth of approximately 18% to 20%.
Gross Margin Expectation: Full-year gross margin expected to be at 79.5%.
Operating Expense Growth: Annual operating expense growth guidance maintained at 10% at the midpoint of the revenue range.
Free Cash Flow in 2026: Company expects to achieve positive free cash flow in 2026.
International Growth in 2026: Anticipates acceleration in international growth in 2026 driven by physician enthusiasm and adoption trends of iFuse-TORQ.
Regulatory Clearances for International Markets: Actively pursuing regulatory clearance to commercialize additional products across several international markets, expected to impact growth meaningfully in 2027 and beyond.
New Product Launches in 2026: Plans to launch two new products in 2026, including a next-generation technology optimized for ambulatory surgery centers in Q1 2026 and a third breakthrough device by late 2026.
Granite Product Reimbursement in 2026: Proposed reimbursement changes may benefit Granite in 2026, including the extension of transitional pass-through payment and a proposed Level 7 APC payment of nearly $28,000 for outpatient procedures.
TNT Technology Growth Potential: TNT technology expected to contribute significantly to growth over the next several years, supported by a new technology add-on payment (NTAP) of more than $4,100 and growing distributor network.
Pipeline of Novel Technologies: Extensive pipeline of novel technologies under development, with several solutions expected to launch over the next 5 years to address poor bone quality.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's strategy for increasing physician density and leveraging operating leverage?
A:The company is focusing on increasing physician density by expanding its platform from SI joint fusion to pelvic fixation and pelvic ring fractures. Only 25% of SI joint surgeons currently perform another procedure type, presenting significant growth opportunities. The company added 330 physicians in the quarter, achieving 27% growth. They aim to target 12,000 surgeons and leverage operating leverage, with a current operating leverage of 1.9x and a target range of 1.25x to 1.75x.
Q:Why did the company raise its guidance midpoint, and what are the expectations for Q4?
A:The company raised its guidance midpoint due to strong Q3 performance, including 21% revenue growth and international growth driven by the TORQ launch. They updated guidance from $193.5-$195.5 million to $198-$200 million. October showed strong momentum, and November trends are also positive. They expect Q4 to be strong despite tougher comparisons.
Q:What are the updates on cash burn expectations for the rest of the year?
A:The company achieved its second consecutive quarter of net cash flow breakeven and its first quarter of positive cash flow from operating activities. They expect to use some cash in Q4 to build surgical capacity and prepare for a new product launch in Q1 of next year. They aim to achieve free cash flow by 2026.
Q:Why does the company believe it can achieve higher growth than the Street's mid-teens growth estimate for next year?
A:The company is comfortable with current consensus estimates but sees potential upside from favorable reimbursement changes, reaccelerating international growth from TORQ, and new product launches. They are being thoughtful about setting expectations.
Q:What is the company's outlook on gross margins and their durability?
A:The company exceeded its gross margin guidance, achieving 79.5% compared to the expected 77%-78%. They expect gross margins to stabilize around 78%-78.5% over the medium term, with potential for further improvement from cost reduction initiatives. Any pressure on gross margins will be offset by operating leverage.
Q:What is the company's plan for increasing territories and addressing seasonality?
A:The company has increased territory productivity to $2.1 million and plans to grow to 100 territories over the next 12-18 months. They are using a hybrid model with territory managers, junior reps, and third-party agents. They aim to offset seasonality by ensuring surgical capacity and engaging physicians.
Q:What are the drivers behind the significant increase in surgeon additions?
A:The company added 330 surgeons in the quarter, a 27% increase, due to targeting spine surgeons, interventionalists, and general ortho trauma surgeons. They are focusing on SI joint fusion and adjacent procedures, leveraging third-party agents, and expanding their addressable market to 12,000 physicians.
Q:How does the company view its new product pipeline and its impact on market TAM?
A:The company plans to launch two new products in 2026, one targeting SI joint fusion in ambulatory surgical centers and another addressing a significant unmet need in spine surgery. These products are expected to expand the market TAM significantly. The company is also focusing on solutions for compromised bone quality.
Q:What is the company's strategy for the TORQ European launch and international growth?
A:The TORQ launch in Europe began in September and is expected to build momentum in Q4 and 2026. The company is evaluating the potential for other products in international markets and sees long-term growth potential in its OUS business.
Q:What is the company's outlook on TNT adoption and its impact on profitability?
A:The company is optimistic about TNT adoption, supported by the NTAP reimbursement effective October 1, which provides a 30% improvement in reimbursement for Medicare patients. They are expanding their commercial footprint and partnering with trauma-focused distributors to drive adoption. They expect significant operating leverage from TNT and other products.
Q:What is the company's long-term profitability outlook compared to traditional spine companies?
A:The company has a unique asset-light model with high ASP and low working capital requirements. They aim to achieve significant operating leverage and margin expansion over time, driven by revenue growth and new product contributions. They expect to outperform traditional spine companies in profitability.
Q:What is the company's approach to engaging interventionalists and expanding the SI joint fusion market?
A:The company is targeting 4,500 interventionalists, focusing on those already performing surgical procedures. They see this as an additive growth opportunity rather than taking business from spine surgeons. They are also benefiting from a proposed 17% increase in reimbursement for SI joint fusion procedures performed in office-based labs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected growth rate for 2026, the exact impact of new product launches on TAM, and the precise timeline for achieving free cash flow. They also used vague language when discussing the durability of gross margins and the potential profitability compared to traditional spine companies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FPA Investor
Granite procedure
Medicare patient
SI procedure
TORQ INTRA
adult deformity
breakthrough device
cash consumption
clearance
date
distributor network
efficiency
excellence
expertise
facility
flow activity
generation
increase number
inflection cash
launch iFuse
learning
market opportunity
number territory
office
outcome patient
patient bone
patient market
physician engagement
scale
site service
solution increase
standard care
strength
technology need
trajectory
volume modality
SIBN Transcript
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong revenue growth, product launches, and strategic partnerships, which are expected to drive future expansion. The Q&A session reveals a conservative guidance increase, but potential upside from new products and partnerships. Although some uncertainties remain, such as specific 2027 growth rates and financial impacts, the overall sentiment is positive due to strong margins, increased reimbursement, and international growth potential.
SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlights strong growth prospects with updated revenue guidance, new product launches, and international expansion plans. The partnership with Smith & Nephew and positive clinical data further support market development. Despite a slight EBITDA miss and gross margin compression, the optimistic guidance and strategic initiatives indicate a positive outlook. The Q&A session did not reveal major concerns, and the market strategy seems solid, suggesting a positive stock price movement in the near term.
SI-BONE, Inc. (SIBN) Q3 2025 Earnings Call Transcript
Positive11-10
The company raised its guidance midpoint due to strong Q3 performance and expects continued positive momentum in Q4. They achieved positive cash flow from operating activities and have a strong product pipeline with international growth prospects. Gross margins exceeded expectations, and they anticipate further improvement. Despite some vague responses, the overall sentiment from the Q&A is positive, with strong growth drivers and strategic initiatives in place.
SIBN Slides
SI-BONE Q1 2026 slides: profitability surges, physician base expands2026-05-11
SI-BONE Q4 2025 slides: profitability milestone as revenue tops $200M2026-02-23
SI-BONE Q2 2025 slides: Revenue jumps 22%, raises full-year guidance2025-08-04
Si-Bone Q1 2025 slides: revenue jumps 25%, achieves positive EBITDA2025-05-05
SIBN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
